Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
CBLI [NASD]
Cleveland BioLabs, Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own1.50% Shs Outstand44.93M Perf Week5.13%
Market Cap73.69M Forward P/E- EPS next Y-0.51 Insider Trans1.51% Shs Float41.44M Perf Month-12.77%
Income-28.54M PEG- EPS next Q-0.15 Inst Own12.47% Short Float5.06% Perf Quarter3.14%
Sales3.36M P/S21.93 EPS this Y87.76% Inst Trans-13.44% Short Ratio7.99 Perf Half Y17.99%
Book/sh-0.07 P/B- EPS next Y10.20% ROA-129.97% Target Price3.67 Perf Year28.13%
Cash/sh0.43 P/C3.85 EPS next 5Y- ROE-862.83% 52W Range1.20 - 2.95 Perf YTD23.31%
Dividend- P/FCF- EPS past 5Y0.00% ROI-961.47% 52W High-44.41% Beta1.83
Dividend %- Quick Ratio- Sales past 5Y38.77% Gross Margin- 52W Low36.67% ATR0.09
Employees85 Current Ratio1.33 Sales Q/Q-94.22% Oper. Margin-920.66% RSI (14)43.15 Volatility5.22% 5.54%
OptionableYes Debt/Eq- EPS Q/Q-299.29% Profit Margin-964.42% Rel Volume0.42 Prev Close1.60
ShortableYes LT Debt/Eq- EarningsMay 09 BMO Payout- Avg Volume262.50K Price1.64
Recom1.70 SMA20-3.33% SMA50-10.31% SMA200-6.15% Volume109,272 Change2.50%
21-Mar-13Initiated Cantor Fitzgerald Buy $4
06-Dec-12Initiated Oppenheimer Outperform $3
04-Dec-12Initiated Burrill Institutional Research Mkt Outperform $4
02-Feb-11Initiated Wedbush Outperform $10
13-Oct-10Downgrade WBB Securities Strong Buy → Hold $6.50 → $6.50
17-Sep-10Reiterated Rodman & Renshaw Mkt Outperform $8 → $11
21-Jul-10Downgrade WBB Securities Strong Buy → Speculative Buy $6.50
29-Sep-09Initiated Rodman & Renshaw Mkt Outperform $8
22-May-13 01:33PM  Profiting From BARDA Contract Awards at Seeking Alpha
08:00AM  Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference PR Newswire
17-May-13 01:04PM  CLEVELAND BIOLABS INC Financials EDGAR Online Financials
14-May-13 08:10PM  4 Healthcare Stock Stories For Tuesday Investment Wellness at Wall St. Cheat Sheet
08:05AM  InPlay: Cleveland Biolabs and Incuron announce US and European patent allowances for curaxins Briefing.com
07:30AM  Cleveland BioLabs and Incuron Announce US and European Patent Allowances for Curaxins GlobeNewswire
09-May-13 05:11PM  Cleveland BioLabs' CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha -6.04%
09:13AM  CORRECTION -- Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress GlobeNewswire
07:30AM  Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress GlobeNewswire
07:07AM  Q1 2013 CLEVELAND BIOLABS INC Earnings Release - Before Market Open CCBN
12:40AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Princ EDGAR Online
08-May-13 07:30AM  Cleveland BioLabs Announces Appointment of Shareholder Representative to Board GlobeNewswire
07-May-13 05:16PM  Isis Initiates ISIS-STAT3 Study Zacks
06-May-13 07:16AM  Zacks Bull and Bear of the Day Highlights: Private Bancorp, Pan American Silver, AVEO Pharmaceuticals, Astellas Pharma and Cleveland BioLabs Zacks
03-May-13 04:30PM  Negative Opinion on AVEO/ALPMY Candidate Zacks
04:00PM  Loss at Aegerion Narrower Than Expected Zacks
01-May-13 08:22AM  Vertex Loss Lower, Kalydeco Outlook Up Zacks -6.18%
07:02AM  InPlay: Cleveland Biolabs, Roswell Park announce publication of studies defining role of liver in activity of Entolimod; results showed that the liver is a major primary target organ of Entolimod Briefing.com
07:00AM  Cleveland BioLabs, Roswell Park Announce Publication of Studies Defining Role of Liver in Activity of Entolimod (CBLB502) GlobeNewswire
30-Apr-13 03:20PM  Double Setback for Gilead Zacks
02:30PM  Merck - Pfizer in Diabetes Deal Zacks
07:56AM  Cleveland BioLabs to Report First Quarter 2013 Financial Results and Provide Operational Update on May 9 GlobeNewswire
29-Apr-13 04:10PM  CHMP in Favor of Celgene's Revlimid Zacks
09:20AM  Geron Narrows Loss; Cuts Jobs Zacks
26-Apr-13 04:00PM  Earnings Increase at The Medicines Co. Zacks
25-Apr-13 11:15AM  Celgene Earnings Rise Y/Y Zacks
11:00AM  Biogen's Earnings Surpass Expectations Zacks
06:41AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
24-Apr-13 04:40PM  Isis Pharma's ISIS-SMNRx Progresses Zacks
12:15PM  Tax Benefit Boosts Amgen Earnings Zacks
23-Apr-13 05:40PM  Merck - BMY in HCV Deal Zacks
09:31AM  Cleveland BioLabs Offers Medical Countermeasures Against Potential Terrorist Attacks at Seeking Alpha
07:02AM  InPlay: Cleveland Biolabs appoints Julia Brown and Anthony Principi as new independent directors and David Hohn, a current director, as Chairman of the board Briefing.com
07:00AM  Cleveland BioLabs Announces Changes to Board of Directors GlobeNewswire
22-Apr-13 05:20PM  Merck In-Licenses from Xenon Zacks +5.38%
17-Apr-13 04:16PM  Achillion's HCV Candidates Progress Zacks
16-Apr-13 06:10PM  Actelion Beats Earnings, Sales Rise Zacks
15-Apr-13 01:20PM  Affymetrix Down to Underperform Zacks -5.97%
12-Apr-13 04:10PM  Repros Gets Additional Patents Zacks
11-Apr-13 04:40PM  Alkermes Announces Restructuring Plan Zacks
10-Apr-13 05:25PM  ADC Data from Seattle Genetics Zacks
08:10AM  Affymetrix to Disappoint in 1Q Zacks
09-Apr-13 04:41AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principa EDGAR Online +5.88%
08-Apr-13 05:45PM  Illumina Introduces TruSight Tumor Zacks
10:54AM  Cleveland BioLabs appoints Jean Viallet to Chief Development Officer theflyonthewall.com
10:53AM  Cleveland BioLabs Strengthens Clinical Development Team GlobeNewswire
04-Apr-13 04:12PM  Positive Data on Repros' Androxal Zacks
02-Apr-13 02:18PM  4 Healthcare Stock Stories for Tuesday Investment Wellness at Wall St. Cheat Sheet
07:03AM  InPlay: Cleveland Biolabs announced the receipt of a Notice of Allowance from the FDA for an Investigational New Drug application for CBL0137. Briefing.com
07:00AM  Cleveland BioLabs and Incuron Announce Notice of Allowance From FDA to Commence Clinical Testing With CBL0137 GlobeNewswire
28-Mar-13 01:18PM  Affymetrix Inks Deal with UK Biobank Zacks
22-Mar-13 01:04PM  CLEVELAND BIOLABS INC Financials EDGAR Online Financials +9.74%
10:04AM  On The Fly: Analyst Initiation Summary theflyonthewall.com
21-Mar-13 02:36PM  GenCorp Gets a Thumbs Up and 4 More Analyst Notes to Read Now at Wall St. Cheat Sheet +8.94%
01:26PM  5 Stocks Under $10 Triggering Breakouts at TheStreet
10:06AM  On The Fly: Analyst Initiation Summary theflyonthewall.com
08:18AM  Zacks #1 Rank Additions for Thursday Zacks
20-Mar-13 09:48PM  Coverage initiated on Cleveland Biolabs by Cantor Fitzgerald Briefing.com
06:57PM  On The Fly: After Hours Movers at theflyonthewall.com
19-Mar-13 03:31PM  A $2.8 Billion Opportunity With All-Hazards Program: Will Cleveland Biolabs Get A Slice? at Seeking Alpha
18-Mar-13 10:17AM  CLEVELAND BIOLABS INC Files SEC form 10-K, Annual Report EDGAR Online
16-Mar-13 07:33PM  New Star Analyst Rankings for Cleveland BioLabs, Inc. StarMine
15-Mar-13 07:42PM  New Star Analyst Rankings for Cleveland BioLabs, Inc. StarMine +8.61%
14-Mar-13 04:27PM  Cleveland BioLabs' CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha -5.63%
09:10AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh EDGAR Online
07:07AM  Q4 2012 CLEVELAND BIOLABS INC Earnings Release - Before Market Open CCBN
07:00AM  Cleveland BioLabs Reports Fourth Quarter and Fiscal 2012 Financial Results and Development Progress GlobeNewswire
08-Mar-13 09:43AM  Cleveland BioLabs to Report Fiscal 2012 Financial Results and Provide Operational Update on March 14 GlobeNewswire
27-Feb-13 09:40AM  Acute Radiation Syndrome, Are We Prepared And Who Is Best Preparing Us? at Seeking Alpha
14-Feb-13 03:20PM  North Korea Tests A Nuke And This Anti-Radiation Stock Is Down? at Seeking Alpha
05-Feb-13 08:20AM  Number of FDA Drug Approvals Reach a 15-Year High in 2012 Marketwire
07:00AM  Cleveland BioLabs to Present at 15th Annual BIO CEO and Investor Conference GlobeNewswire
04-Feb-13 10:24AM  Can Cleveland BioLabs Fight Radiation With This New Drug? at Seeking Alpha +12.58%
31-Jan-13 10:48AM  4 Speculative Biotech Stocks To Consider at Seeking Alpha
24-Jan-13 07:00AM  Cleveland BioLabs to Present at BARDA and NIAID Sponsored Symposium on Development of Radiation Medical Countermeasures GlobeNewswire
07-Dec-12 10:05AM  On The Fly: Analyst Initiation Summary theflyonthewall.com
06-Dec-12 01:16PM  Crocs Initiated at Outperform and 1 Initiated Stock on the Move at Wall St. Cheat Sheet +6.43%
01:10PM  5 Under-$10 Charts Showing Major Upside at TheStreet
10:09AM  On The Fly: Analyst Initiation Summary theflyonthewall.com
05-Dec-12 11:15PM  Coverage initiated on Cleveland Biolabs by Oppenheimer Briefing.com
04-Dec-12 01:39PM  Imperva Initiated at Outperform and 3 Must-See Initiated Stocks at Wall St. Cheat Sheet
07:00AM  Cleveland BioLabs to Present at Oppenheimer 23rd Annual Healthcare Conference GlobeNewswire
03-Dec-12 11:21PM  Coverage initiated on Cleveland Biolabs by Burrill Institutional Research Briefing.com
27-Nov-12 07:02AM  InPlay: Cleveland Biolabs, a subsidiary of Cleveland BioLabs, signs contract for ~$4.6 mln with Russian Ministry of Industry and Trade for Development of Xenomycins Briefing.com
07:00AM  Panacela Labs, a Subsidiary of Cleveland BioLabs, Signs Contract for Approximately $4.6 Million With Russian Ministry of Industry and Trade for Development of Xenomycins GlobeNewswire
16-Nov-12 01:04PM  CLEVELAND BIOLABS INC Financials EDGAR Online Financials
09-Nov-12 04:33PM  CLEVELAND BIOLABS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
08-Nov-12 10:19PM  Cleveland BioLabs' CEO Discusses Q3 2012 Results - Earnings Call Transcript at Seeking Alpha
07:15AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh EDGAR Online
07:07AM  Q3 2012 CLEVELAND BIOLABS INC Earnings Release - Before Market Open CCBN
07:00AM  Cleveland BioLabs Reports Third Quarter 2012 Financial Results and Development Progress GlobeNewswire
06-Nov-12 07:00AM  Cleveland BioLabs Announces Publication of Studies on Effect of Entolimod(TM) (CBLB502) on Graft-Versus-Tumor Activity in Models of Allogeneic Bone Marrow Transplantation GlobeNewswire
30-Oct-12 07:00AM  Cleveland BioLabs to Report Third Quarter Financial Results and Provide Operational Update on November 8 GlobeNewswire
25-Oct-12 07:02AM  Department of Defense Chemical Biological and Medical Systems Continues Funding Under Development Contract With Cleveland BioLabs for Entolimod(TM) (CBLB502) GlobeNewswire
23-Oct-12 02:29PM  Cleveland Biolabs: Gunning For $50 Million In Government Funding at Seeking Alpha -6.67%
22-Oct-12 06:01AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme EDGAR Online
19-Oct-12 11:42AM  Health Care Plunge: 4 Stocks Falling Hard at Motley Fool -26.21%
09:41AM  Cleveland BioLabs shares plummet after stock offer AP
09:02AM  InPlay: Cleveland Biolabs priced offering of 7.5 mln units at $2.00 per unit Briefing.com
09:01AM  Cleveland BioLabs Prices $15 Million Public Offering of Common Stock and Warrants GlobeNewswire
Cleveland BioLabs, Inc., a clinical-stage biotechnology company, engages in the research, development, and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation, and counteract the genotoxic effects of radio- and chemotherapies for oncology patients. Its lead drug is Entolimod, which is being developed for radiation countermeasure and cancer treatment. The company's products candidates also include CBL0102, which is undergoing a Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and CBL0137, which is in multi-center, single agent, dose escalation Phase I study of the oral formulation in subjects with advanced solid tumors. In addition, it has pre-clinical stage products candidates, such as CBLB612, an inducer and mobilizer of hematopoietic stem cells; Revercom, a cancer drug candidate comprising a liposome-packaged proprietary small molecule named Reversan; Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin; Arkil, a prospective treatment for prostate cancer; Antimycon, a proprietary small molecule lead compound generated to selectively target and inactivate oncoproteins of the Myc family; and Xenomycin family of compounds, which have a range of potential applications as antimicrobial and anti-fungal agents. The company has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DiCorleto Paul EDirectorMay 21Buy1.616,2109,99731,866May 23 07:34 PM
SALUCK RANDY S.DirectorMay 17Buy1.603,5005,61384,500May 21 09:02 PM
Antal JamesDirectorMar 15Buy1.563,7005,7728,000Mar 18 02:13 PM
Antal JamesDirectorSep 21Buy2.602,3166,02227,258Sep 25 06:01 AM
Hohn David CDirectorJul 02Buy1.611,0001,6109,584Jul 05 06:00 AM
Antal JamesDirectorJun 15Buy1.763,4005,98424,942Jul 03 05:21 PM